Compass Pathways plc announced 26-week results from its Phase 3 COMP006 trial of COMP360, a synthetic psilocybin formulation for treatment-resistant depression. In the 25 mg dose arm, 39% of participants achieved a clinically meaningful reduction in MADRS scores by week 6 and maintained benefit through week 26. The company is on track to complete its rolling New Drug Application (NDA) submission to the FDA in Q4 2026, with a potential commercial launch in the first half of 2027. Compass Pathways plc is a biotechnology company developing mental health treatments.